## Cristan A Farmer

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/898929/publications.pdf

Version: 2024-02-01

94 papers

3,489 citations

34 h-index 53 g-index

97 all docs

97 docs citations

97 times ranked 4848 citing authors

#	Article	IF	CITATIONS
1	Making Research Possible: Barriers and Solutions For Those With ASD and ID. Journal of Autism and Developmental Disorders, 2022, 52, 4646-4650.	1.7	10
2	Prospective association of psychological pain and hopelessness with suicidal thoughts. Journal of Affective Disorders, 2022, 308, 243-248.	2.0	8
3	The kynurenine pathway and bipolar disorder: intersection of the monoaminergic and glutamatergic systems and immune response. Molecular Psychiatry, 2021, 26, 4085-4095.	4.1	48
4	Sex differences in scores on standardized measures of autism symptoms: a multisite integrative data analysis. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2021, 62, 97-106.	3.1	74
5	Low Incidence of Postdural Puncture Headache Further Reduced With Atraumatic Spinal Needle: A Retrospective Cohort Study. Pediatric Neurology, 2021, 114, 35-39.	1.0	4
6	Extracting Latent Subdimensions of Social Communication: A Cross-Measure Factor Analysis. Journal of the American Academy of Child and Adolescent Psychiatry, 2021, 60, 768-782.e6.	0.3	16
7	Clinical trials for rapid changes in suicidal ideation: Lessons from ketamine. Suicide and Life-Threatening Behavior, 2021, 51, 27-35.	0.9	5
8	Patterns of delay in early gross motor and expressive language milestone attainment in probands with genetic conditions versus idiopathic ASD from SFARI registries. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2021, 62, 1297-1307.	3.1	13
9	The contribution of platelets to peripheral BDNF elevation in children with autism spectrum disorder. Scientific Reports, 2021, 11, 18158.	1.6	7
10	Age of walking and intellectual ability in autism spectrum disorder and other neurodevelopmental disorders: a populationâ€based study. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2021, 62, 1070-1078.	3.1	6
11	Standardized Observation Analogue Procedure in the Treatment of Severe Childhood Aggression Study. Journal of Child and Adolescent Psychopharmacology, 2020, 30, 48-54.	0.7	3
12	Concordance of the Vineland Adaptive Behavior Scales, second and third editions. Journal of Intellectual Disability Research, 2020, 64, 18-26.	1.2	37
13	Neurodevelopmental Characterization of Young Children Diagnosed with Niemann-Pick Disease, Type C1. Journal of Developmental and Behavioral Pediatrics, 2020, 41, 388-396.	0.6	6
14	Dr. Bishop et al. Reply. Journal of the American Academy of Child and Adolescent Psychiatry, 2020, 59, 1200-1202.	0.3	1
15	Psychometric Study of the Social Responsiveness Scale in Phelan–McDermid Syndrome. Autism Research, 2020, 13, 1383-1396.	2.1	14
16	Measurement of Subcategories of Repetitive Behaviors in Autistic Adolescents and Adults. Autism in Adulthood, 2020, 2, 48-60.	4.0	10
17	State of the Field: Differentiating Intellectual Disability From Autism Spectrum Disorder. Frontiers in Psychiatry, 2019, 10, 526.	1.3	135
18	Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant. Neuropsychopharmacology, 2019, 44, 1233-1238.	2.8	35

#	Article	IF	Citations
19	The Need for a Developmentally Based Measure of Social Communication Skills. Journal of the American Academy of Child and Adolescent Psychiatry, 2019, 58, 555-560.	0.3	20
20	Multimodal imaging reveals a complex pattern of dysfunction in corticolimbic pathways in major depressive disorder. Human Brain Mapping, 2019, 40, 3940-3950.	1.9	36
21	Long-Term Neuropsychological Outcomes from an Open-Label Phase I/IIa Trial of 2-Hydroxypropyl-1²-Cyclodextrins (VTS-270) in Niemann-Pick Disease, Type C1. CNS Drugs, 2019, 33, 677-683.	2.7	28
22	Effective Medications for Treating Individuals with Autism Spectrum Disorder. Pediatric School Psychology, 2019, , 83-98.	0.0	2
23	Neurophysiological Changes Associated with Antidepressant Response to Ketamine Not Observed in a Negative Trial of Scopolamine in Major Depressive Disorder. International Journal of Neuropsychopharmacology, 2019, 22, 10-18.	1.0	27
24	Attendance and Engagement in Parent Training Predict Child Behavioral Outcomes in Children Pharmacologically Treated for Attention-Deficit/Hyperactivity Disorder and Severe Aggression. Journal of Child and Adolescent Psychopharmacology, 2019, 29, 90-99.	0.7	11
25	Disentangling the association of depression on the anti-fatigue effects of ketamine. Journal of Affective Disorders, 2019, 244, 42-45.	2.0	11
26	Functional brain connectivity in electrical status epilepticus in sleep., 2019, 21, 55-64.		0
27	Clinical Trial of the Potassium Channel Activator Diazoxide for Major Depressive Disorder Halted Due to Intolerability. Journal of Clinical Psychopharmacology, 2018, 38, 243-246.	0.7	3
28	Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression. Journal of Affective Disorders, 2018, 232, 310-315.	2.0	87
29	Parsing the heterogeneity of depression: An exploratory factor analysis across commonly used depression rating scales. Journal of Affective Disorders, 2018, 231, 51-57.	2.0	62
30	Trajectories of cognitive development in toddlers with language delays. Research in Developmental Disabilities, 2018, 81, 65-72.	1.2	8
31	Psychometric Evaluation of the Caregiver Burden Inventory in Children and Adolescents With PANS. Journal of Pediatric Psychology, 2018, 43, 749-757.	1.1	32
32	Talking About Death or Suicide: Prevalence and Clinical Correlates in Youth with Autism Spectrum Disorder in the Psychiatric Inpatient Setting. Journal of Autism and Developmental Disorders, 2018, 48, 3702-3710.	1.7	55
33	Longitudinal outcomes of children with pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections (PANDAS). European Child and Adolescent Psychiatry, 2018, 27, 637-643.	2.8	14
34	PET radioligand binding to translocator protein (TSPO) is increased in unmedicated depressed subjects. EJNMMI Research, 2018, 8, 57.	1.1	144
35	Characterization of autism spectrum disorder and neurodevelopmental profiles in youth with XYY syndrome. Journal of Neurodevelopmental Disorders, 2018, 10, 30.	1.5	23
36	Cerebrospinal fluid vasopressin and symptom severity in children with autism. Annals of Neurology, 2018, 84, 611-615.	2.8	40

#	Article	IF	CITATIONS
37	Classifying and characterizing the development of adaptive behavior in a naturalistic longitudinal study of young children with autism. Journal of Neurodevelopmental Disorders, 2018, 10, 1.	1.5	79
38	Characterizing the course of suicidal ideation response to ketamine. Journal of Affective Disorders, 2018, 241, 86-93.	2.0	44
39	SOCIOEMOTIONAL AND BEHAVIORAL PROBLEMS IN TODDLERS WITH LANGUAGE DELAY. Infant Mental Health Journal, 2018, 39, 569-580.	0.7	13
40	Spindle activity in young children with autism, developmental delay, or typical development. Neurology, 2018, 91, e112-e122.	1.5	40
41	The Burden of Caring for a Child or Adolescent With Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS). Journal of Clinical Psychiatry, 2018, 80, .	1.1	20
42	Prospective phenotyping of NGLY1-CDDG, the first congenital disorder of deglycosylation. Genetics in Medicine, 2017, 19, 160-168.	1.1	124
43	The Treatment of Severe Childhood Aggression Study: 12 Weeks of Extended, Blinded Treatment in Clinical Responders. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 52-65.	0.7	21
44	Identification of Developmental and Behavioral Markers Associated With Genetic Abnormalities in Autism Spectrum Disorder. American Journal of Psychiatry, 2017, 174, 576-585.	4.0	73
45	Serum and cerebrospinal fluid immune mediators in children with autistic disorder: a longitudinal study. Molecular Autism, 2017, 8, 1.	2.6	127
46	Clinical Implications From the Treatment of Severe Childhood Aggression (TOSCA) Study: A Re-Analysis and Integration of Findings. Journal of the American Academy of Child and Adolescent Psychiatry, 2017, 56, 1026-1033.	0.3	13
47	Riluzole Serum Concentration in Pediatric Patients Treated for Obsessive-Compulsive Disorder. Journal of Clinical Psychopharmacology, 2017, 37, 713-716.	0.7	3
48	Pediatric Acute-Onset Neuropsychiatric Syndrome Response to Oral Corticosteroid Bursts: An Observational Study of Patients in an Academic Community-Based PANS Clinic. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 629-639.	0.7	31
49	Effect of Early and Prophylactic Nonsteroidal Anti-Inflammatory Drugs on Flare Duration in Pediatric Acute-Onset Neuropsychiatric Syndrome: An Observational Study of Patients Followed by an Academic Community-Based Pediatric Acute-Onset Neuropsychiatric Syndrome Clinic. Journal of Child and Adolescent Psychopharmacology. 2017, 27, 619-628.	0.7	37
50	Describing Function in ASD: Using the DSM-5 and Other Methods to Improve Precision. Journal of Autism and Developmental Disorders, 2017, 47, 2938-2941.	1.7	11
51	Risperidone Added to Psychostimulant in Children with Severe Aggression and Attention-Deficit/Hyperactivity Disorder: Lack of Effect on Attention and Short-Term Memory. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 117-124.	0.7	8
52	Commentary: Lingering questions about the Social Responsiveness Scale short form. A commentary on Sturm etÂal. (2017). Journal of Child Psychology and Psychiatry and Allied Disciplines, 2017, 58, 1062-1064.	3.1	16
53	Standardized Behavior Checklists. , 2017, , 1-2.		0
54	Cohort study of neurocognitive functioning and adaptive behaviour in children and adolescents with Niemannâ€Pick Disease type C1. Developmental Medicine and Child Neurology, 2016, 58, 262-269.	1.1	13

#	Article	IF	CITATIONS
55	CSF concentrations of 5-methyltetrahydrofolate in a cohort of young children with autism. Neurology, 2016, 86, 2258-2263.	1.5	25
56	Severely Aggressive Children Receiving Stimulant Medication Versus Stimulant and Risperidone: 12-Month Follow-Up of the TOSCA Trial. Journal of the American Academy of Child and Adolescent Psychiatry, 2016, 55, 469-478.	0.3	37
57	Confirmation of the Factor Structure and Measurement Invariance of the Children's Scale of Hostility and Aggression: Reactive/Proactive in Clinic-Referred Children With and Without Autism Spectrum Disorder. Journal of Child and Adolescent Psychopharmacology, 2016, 26, 10-18.	0.7	12
58	Randomized, Controlled Trial of Intravenous Immunoglobulin for Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections. Journal of the American Academy of Child and Adolescent Psychiatry, 2016, 55, 860-867.e2.	0.3	78
59	Development, behavior, and biomarker characterization of Smith-Lemli-Opitz syndrome: an update. Journal of Neurodevelopmental Disorders, 2016, 8, 12.	1.5	45
60	Cortical thickness change in autism during early childhood. Human Brain Mapping, 2016, 37, 2616-2629.	1.9	41
61	Autism Spectrum Disorder, Intellectual Disability, and Delayed Walking. Pediatrics, 2016, 137, e20152959.	1.0	32
62	Concurrent validity of the differential ability scales, second edition with the Mullen Scales of Early Learning in young children with and without neurodevelopmental disorders. Child Neuropsychology, 2016, 22, 556-569.	0.8	54
63	State-Dependent Differences in Functional Connectivity in Young Children With Autism Spectrum Disorder. EBioMedicine, 2015, 2, 1905-1915.	2.7	33
64	Measurement of Nonverbal IQ in Autism Spectrum Disorder: Scores in Young Adulthood Compared to Early Childhood. Journal of Autism and Developmental Disorders, 2015, 45, 966-974.	1.7	67
65	Longitudinal study of symptom severity and language in minimally verbal children with autism. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2015, 56, 97-104.	3.1	71
66	Evaluation of Periodic Limb Movements in Sleep and Iron Status in Children With Autism. Pediatric Neurology, 2015, 53, 343-349.	1.0	28
67	Comorbid Anxiety and Social Avoidance in Treatment of Severe Childhood Aggression: Response to Adding Risperidone to Stimulant and Parent Training; Mediation of Disruptive Symptom Response. Journal of Child and Adolescent Psychopharmacology, 2015, 25, 203-212.	0.7	14
68	Participant Satisfaction in a Study of Stimulant, Parent Training, and Risperidone in Children with Severe Physical Aggression. Journal of Child and Adolescent Psychopharmacology, 2015, 25, 225-233.	0.7	8
69	Comorbid Symptomatology Moderates Response to Risperidone, Stimulant, and Parent Training in Children with Severe Aggression, Disruptive Behavior Disorder, and Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 2015, 25, 213-224.	0.7	29
70	Factor Validity of a Proactive and Reactive Aggression Rating Scale. Journal of Child and Family Studies, 2015, 24, 2734-2744.	0.7	7
71	Aggression in children with autism spectrum disorders and a clinic-referred comparison group. Autism, 2015, 19, 281-291.	2.4	65
72	12-Week, Placebo-Controlled Trial of Add-on Riluzole in the Treatment of Childhood-Onset Obsessive–Compulsive Disorder. Neuropsychopharmacology, 2014, 39, 1453-1459.	2.8	63

#	Article	IF	CITATIONS
73	Risperidone Added to Parent Training and Stimulant Medication: Effects on Attention-Deficit/Hyperactivity Disorder, Oppositional Defiant Disorder, Conduct Disorder, and Peer Aggression. Journal of the American Academy of Child and Adolescent Psychiatry, 2014, 53, 948-959.e1.	0.3	68
74	What Does Risperidone Add to Parent Training and Stimulant for Severe Aggression in Child Attention-Deficit/Hyperactivity Disorder?. Journal of the American Academy of Child and Adolescent Psychiatry, 2014, 53, 47-60.e1.	0.3	125
75	Pharmacotherapy for the Core Symptoms in Autistic Disorder: Current Status of the Research. Drugs, 2013, 73, 303-314.	4.9	87
76	Pharmacological Intervention for Disruptive Behaviors in Intellectual and Developmental Disabilities. International Review of Research in Developmental Disabilities, 2013, 44, 281-325.	0.6	4
77	Dietary Adequacy of Children with Autism Compared with Controls and the Impact of Restricted Diet. Journal of Developmental and Behavioral Pediatrics, 2013, 34, 449-459.	0.6	58
78	Repetitive Behavior and Restricted Interests in Young Children with Autism: Comparisons with Controls and Stability Over 2 Years. Autism Research, 2013, 6, 584-595.	2.1	50
79	The <scp>ADOS</scp> Calibrated Severity Score: Relationship to Phenotypic Variables and Stability over Time. Autism Research, 2012, 5, 267-276.	2.1	94
80	Placebo-Controlled Pilot Trial of Mecamylamine for Treatment of Autism Spectrum Disorders. Journal of Child and Adolescent Psychopharmacology, 2012, 22, 198-205.	0.7	41
81	Predictors and Moderators of Parent Training Efficacy in a Sample of Children with Autism Spectrum Disorders and Serious Behavioral Problems. Journal of Autism and Developmental Disorders, 2012, 42, 1037-1044.	1.7	15
82	Demystifying moderators and mediators in intellectual and developmental disabilities research: a primer and review of the literature. Journal of Intellectual Disability Research, 2012, 56, 1148-1160.	1.2	25
83	Aggressive behavior in a sample of children with autism spectrum disorders. Research in Autism Spectrum Disorders, 2011, 5, 317-323.	0.8	117
84	The treatment of severe child aggression (TOSCA) study: Design challenges. Child and Adolescent Psychiatry and Mental Health, 2011, 5, 36.	1.2	30
85	Aripiprazole for the treatment of irritability associated with autism. Expert Opinion on Pharmacotherapy, 2011, 12, 635-640.	0.9	35
86	Moderators, Mediators, and Other Predictors of Risperidone Response in Children with Autistic Disorder and Irritability. Journal of Child and Adolescent Psychopharmacology, 2010, 20, 83-93.	0.7	53
87	Serum Ferritin and Amphetamine Response in Youth with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 2010, 20, 495-502.	0.7	57
88	Psychometric properties of the Children's Scale of Hostility and Aggression: Reactive/Proactive (C-SHARP). Research in Developmental Disabilities, 2010, 31, 270-280.	1.2	43
89	Individuals with Intellectual Disability. , 2010, , 600-616.		0
90	Development of the Children's Scale of Hostility and Aggression: Reactive/Proactive (C-SHARP). Research in Developmental Disabilities, 2009, 30, 1155-1167.	1.2	80

#	Article	IF	CITATIONS
91	Treatment of Inattention, Overactivity, and Impulsiveness in Autism Spectrum Disorders. Child and Adolescent Psychiatric Clinics of North America, 2008, 17, 713-738.	1.0	69
92	Psychotropic Medication Research in Children and Adolescents: Empirical Findings and Ethical Implications. Journal of Empirical Research on Human Research Ethics, 2008, 3, 39-47.	0.6	4
93	Project MED: Effects of aMedicationEDucation Booklet Series for Individuals With Intellectual Disabilities. Intellectual and Developmental Disabilities, 2007, 45, 33-45.	0.6	13
94	Intellectual and developmental disabilities , 0, , 335-351.		1